Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.

In this randomized controlled trial on four commercial grazing dairy farms, we investigated whether pegbovigrastim (PEG) treatment affects clinical mastitis (CM) and uterine disease (i.e. retained placenta (RP), metritis and endometritis) occurrence during a full lactation. The association of prepar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joaquín Barca, Ana Meikle, Mette Bouman, Giovanni Gnemmi, Rodrigo Ruiz, Ynte H Schukken
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/29aca7c40ff14c31b43280f38838fe7e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29aca7c40ff14c31b43280f38838fe7e
record_format	dspace
spelling	oai:doaj.org-article:29aca7c40ff14c31b43280f38838fe7e2021-12-02T20:11:14ZEffect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.1932-620310.1371/journal.pone.0252418https://doaj.org/article/29aca7c40ff14c31b43280f38838fe7e2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252418https://doaj.org/toc/1932-6203In this randomized controlled trial on four commercial grazing dairy farms, we investigated whether pegbovigrastim (PEG) treatment affects clinical mastitis (CM) and uterine disease (i.e. retained placenta (RP), metritis and endometritis) occurrence during a full lactation. The association of prepartum body condition score and prepartum non-esterified fatty acid (NEFA) concentration with disease occurrence was also evaluated. Holstein cows were randomly assigned to one of two treatments: first PEG dose approximately 7 d before the expected calving date and a second dose within 24 h after calving (PEG) compared to untreated controls (Control). In total, 2,153 animals were included in the study: 733 primiparous cows (Control = 391, PEG = 342) and 1420 multiparous cows (Control = 723, PEG = 697). Treatment effects were evaluated with generalized linear mixed models and Cox's proportional hazard models. Treatment with PEG reduced the occurrence of a first case of CM during the first 30 days in milk (DIM) by 24.6% and reduced the hazard of a first case and the rate of total cases of CM during the full lactation. All PEG treatment effects were independent of parity. Prepartum body condition score interacted with PEG treatment: in over-conditioned cows, PEG reduced the occurrence of a first case of CM during the first 30 DIM by 49.5%. The hazard analysis of a first case of CM during the full lactation suggested that the preventive effect of PEG disappeared with increasing DIM. Treatment with PEG did not affect the occurrence of RP or metritis. Pegbovigrastim treated cows with metritis subsequently showed a reduced occurrence of endometritis compared to control cows with metritis. Pegbovigrastim reduces the occurrence of CM particularly in cows at risk of elevated lipid mobilization, and PEG ameliorates the uterine healing process in cows that experienced metritis.Joaquín BarcaAna MeikleMette BoumanGiovanni GnemmiRodrigo RuizYnte H SchukkenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0252418 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Joaquín Barca Ana Meikle Mette Bouman Giovanni Gnemmi Rodrigo Ruiz Ynte H Schukken Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
description	In this randomized controlled trial on four commercial grazing dairy farms, we investigated whether pegbovigrastim (PEG) treatment affects clinical mastitis (CM) and uterine disease (i.e. retained placenta (RP), metritis and endometritis) occurrence during a full lactation. The association of prepartum body condition score and prepartum non-esterified fatty acid (NEFA) concentration with disease occurrence was also evaluated. Holstein cows were randomly assigned to one of two treatments: first PEG dose approximately 7 d before the expected calving date and a second dose within 24 h after calving (PEG) compared to untreated controls (Control). In total, 2,153 animals were included in the study: 733 primiparous cows (Control = 391, PEG = 342) and 1420 multiparous cows (Control = 723, PEG = 697). Treatment effects were evaluated with generalized linear mixed models and Cox's proportional hazard models. Treatment with PEG reduced the occurrence of a first case of CM during the first 30 days in milk (DIM) by 24.6% and reduced the hazard of a first case and the rate of total cases of CM during the full lactation. All PEG treatment effects were independent of parity. Prepartum body condition score interacted with PEG treatment: in over-conditioned cows, PEG reduced the occurrence of a first case of CM during the first 30 DIM by 49.5%. The hazard analysis of a first case of CM during the full lactation suggested that the preventive effect of PEG disappeared with increasing DIM. Treatment with PEG did not affect the occurrence of RP or metritis. Pegbovigrastim treated cows with metritis subsequently showed a reduced occurrence of endometritis compared to control cows with metritis. Pegbovigrastim reduces the occurrence of CM particularly in cows at risk of elevated lipid mobilization, and PEG ameliorates the uterine healing process in cows that experienced metritis.
format	article
author	Joaquín Barca Ana Meikle Mette Bouman Giovanni Gnemmi Rodrigo Ruiz Ynte H Schukken
author_facet	Joaquín Barca Ana Meikle Mette Bouman Giovanni Gnemmi Rodrigo Ruiz Ynte H Schukken
author_sort	Joaquín Barca
title	Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
title_short	Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
title_full	Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
title_fullStr	Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
title_full_unstemmed	Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
title_sort	effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/29aca7c40ff14c31b43280f38838fe7e
work_keys_str_mv	AT joaquinbarca effectofpegbovigrastimonclinicalmastitisanduterinediseaseduringafulllactationingrazingdairycows AT anameikle effectofpegbovigrastimonclinicalmastitisanduterinediseaseduringafulllactationingrazingdairycows AT mettebouman effectofpegbovigrastimonclinicalmastitisanduterinediseaseduringafulllactationingrazingdairycows AT giovannignemmi effectofpegbovigrastimonclinicalmastitisanduterinediseaseduringafulllactationingrazingdairycows AT rodrigoruiz effectofpegbovigrastimonclinicalmastitisanduterinediseaseduringafulllactationingrazingdairycows AT yntehschukken effectofpegbovigrastimonclinicalmastitisanduterinediseaseduringafulllactationingrazingdairycows
_version_	1718374873241223168

Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows.

Ejemplares similares